MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated July 12, 2022,	4. Expiration Date: July 31, 2025
1. Lakeland Medical Center - St. Joseph 2. 1234 Napier Ave. St. Joseph, MI 49085	3. License No.: 21-04177-01 is amended in its entirety to read as follows:	5. Docket No.: 030-02049 Reference No.:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie total	C. For any use permitted by 10 CFR 35.300.
D. Iodine-125 permitted by 10 CFR 35.400	D. Sealed Sources (Bard Brachytherapy, Inc., Model STM-1251; North American Scientific, Inc., Model MED 3631)	D. 1 curie total	D. For any manual brachytherapy procedure permitted by 10 CFR 35.400.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License No.: 21-04177-01

Amendment No. 110

Docket or Reference No.: 030-02049

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
E. Iridium-192 permitted by 10 CFR 35.400	E. Sealed Sources (Best Medical International, Inc., Model 81-01 Series)	E. 100 millicuries total	E. For any manual brachytherapy procedure permitted by 10 CFR 35.400.
F. Palladium-103 permitted by 10 CFR 35.400	F. Sealed Sources (Theragenics Corporation, Model TheraSeed 200)	F. 1 curie total	F. For any manual brachytherapy procedure permitted by 10 CFR 35.400.
G. Cesium-131 permitted by 10 CFR 35.400	G. Sealed Sources (IsoRay Medical, Inc., Model CS-1)	G. 1 curie total	G. For any manual brachytherapy procedure permitted by 10 CFR 35.400.
H. Yttrium-90 permitted by 10 CFR 35.1000	H. Microspheres (Sirtex Wilmington LLC, Sirtex Medical Limited, Sirtex Singapore Manufacturing Pte Ltd, Model SIR-Spheres)	H. 3 curies total	H. For medical use as permitted by 10 CFR 35.1000 in a SIR-Spheres brachytherapy afterloader.

MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 21-04177-01	Docket or Reference No.: 030-02049
	Amendment No. 110	

CONDITIONS

10. A. Licensed material listed in Item Nos. 6.A. through 6.H. shall be used at the licensee's facilities located at Lakeland Medical Center - St. Joseph, 1234 Napier Ave., St. Joseph, Michigan 49085.

B. Licensed material listed in Item Nos. 6.A. through 6.D. shall be used at the licensee's facilities located at Lakeland Medical Center - Niles, 31 North St. Joseph Ave., Niles, Michigan 49120.

11. The Radiation Safety Officer (RSO) for this license is David E. Sieffert, M.S.

12. Licensed material shall only be used by, or under the supervision of:

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)	Material and Use
Dilip Arora, M.D.	10 CFR 35.100,10 CFR 35.200
Brendan Banyon, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)
Ryan Daily, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)
Dennis L. Gibbs, D.O.	10 CFR 35.100,10 CFR 35.200
Benjamin T. Gielda, M.D.	10 CFR 35.300,10 CFR 35.400
Roman Hyszczak, M.D.	10 CFR 35.100,10 CFR 35.200
Willie Edward Lawrence, M.D.	10 CFR 35.200
Dale G. Leffler, D.O.	10 CFR 35.200
Richard Lichtenberg, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Ogubay Mesmer, M.D.	10 CFR 35.100,10 CFR 35.200

MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 21-04177-01	Docket or Reference No.: 030-02049
	Amendment No. 110	

Authorized User (M.D.,D.O.,etc.)	Material and Use
Peter Paximadis, M.D.	10 CFR 35.300 (limited to parenteral administration of radium-223),10 CFR 35.400
Thomas K. Pow, M.D.	10 CFR 35.100,10 CFR 35.200
Joel T. VanderLugt, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131), 10 CFR 35.1000 (limited to yttrium-90 as SIR-Spheres)

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.

A. Application dated January 19, 2015 (ML15021A571)
B. Letter dated July 13, 2015 (ML15202A170)
C. Letter dated April 5, 2016 (ML16099A174)
D. Letter dated July 7, 2016 (ML16195A125)
E. Letter dated September 6, 2016 (ML16251A335)
F. Letter dated March 21, 2017 (ML17101A644)
G. Letter dated January 10, 2018 (ML18010A910)
H. Letter dated April 8, 2019 (ML18010A910)
I. Letter dated April 15, 2020 (ML20107F775)
J. Letter dated October 5, 2020 (ML20287A131)

MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 21-04177-01	Docket or Reference No.: 030-02049
	Amendment No. 110	

K. Letter dated December 4, 2020 (ML20346A188)
L. Letter dated February 3, 2021 (ML21040A444)
M. Letter dated March 28, 2022 (ML22090A099)
N. Letter dated July 12, 2022 (ML22201A060)
O. September 19, 2022 (ML22263A287)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: September 22, 2022

By: Magdalena R. Gryglak
Digitally signed by Magdalena R. Gryglak
Date: 2022.09.22 11:18:05 -05'00'

Magdalena R. Gryglak
Region 3